FOSCARNET PACKAGE INSERT PDF

Name of the medicinal product. Foscavir 24 mg/ml Solution for Infusion. 2. Qualitative and quantitative composition. Foscarnet trisodium hexahydrate 24 mg /ml. Package leaflet: Information for the user. Foscavir®. 24 mg/ml Solution for Infusion foscarnet. M UK. Read all of this leaflet carefully before you start. Foscavir™ (Foscarnet Sodium) Injection Product Insert rubber latex has not been used in the manufacture of this device or drug container closure system.

Author: Voodooktilar Kazisida
Country: Suriname
Language: English (Spanish)
Genre: History
Published (Last): 17 November 2016
Pages: 39
PDF File Size: 11.12 Mb
ePub File Size: 3.86 Mb
ISBN: 180-3-22134-195-7
Downloads: 81548
Price: Free* [*Free Regsitration Required]
Uploader: Mikaran

Mefloquine alone has not been reported to cause QT prolongation. Exercise caution when administering the drug to patients with a history of QT prolongation, long QT syndrome, electrolyte imbalances, or other risk factors for QT prolongation. An additive effect is proposed since seizures have been associated with ciprofloxacin and foscarnet independently.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as buprenorphine.

In addition, there are postmarketing reports of TdP. This medicinal product must not be mixed with any other pac,age products except those mentioned in section 4. Foscarnet is not metabolized in the liver. Sorafenib has been associated with QT prolongation.

The infusion time should not be shorter than 1 hour. The effects of this deposition on skeletal development have not been studied. Due to Foscavir’s propensity to chelate bivalent metal ions, such as calcium, Foscavir administration may be associated with an acute decrease of ionised serum calcium proportional to the rate of Foscavir infusion, which may not be reflected in total serum calcium levels.

  ASTM D7028 PDF

Cardiac disease, electrolyte imbalance, hypocalcemia, neurological disease, seizure disorder, seizures.

Foscavir 24 mg/ml Solution for Infusion – Summary of Product Characteristics (SmPC) – (eMC)

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as droperidol. The electrolytes, especially calcium and magnesium, should be assessed prior to and during Foscavir therapy and deficiencies corrected. Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: Foscxrnet the first dose, the hydration fluid should be administered concurrently with each drug infusion.

QT prolongation has also occurred during therapeutic use of atomoxetine and following overdose. Moderate Foscarnet-induced hypokalemia or hypomagnesemia can potentiate the cardiac toxicity of arsenic trioxide or levomethadyl. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as procainamide.

Foscavir 24 mg/ml Solution for Infusion

Major The fosdarnet of renal toxicity may be increased if foscarnet is used in conjunction with other nephrotoxic agents such as cisplatin. The renal function of patients with renal disease or receiving concomitant treatment with other nephrotoxic medicinal products must be closely monitored see section 4.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as hydroxychloroquine.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as fluoxetine. Telithromycin is also associated with QT prolongation and TdP. Please refer to section 5. For CNS infections, see encephalitis. Major Avoid coadministration of ribociclib with foscarnet due to an increased risk for QT prolongation and torsade de pointes TdP.

  IRR99 REGULATIONS PDF

Foscarnet is administered by intravenous packabe. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as vardenafil. Use of topically administrated preparations containing bacitracin, especially when applied to large surface areas, may have additive nephrotoxic potential with foscarnet.

PDR Search

Human studies regarding use of foscarnet during pregnancy have not been conducted; however in animal studies, exposure to foscarnet was associated with a slight increase in skeletal anomalies.

Major When possible, avoid concurrent use fkscarnet foscarnet with other drugs known to prolong the QT interval, such as ezogabine.

We do not record any personal information entered above. Romidepsin has been reported to prolong the QT interval. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong foscarhet QT interval, such as romidepsin. Bismuth Subcitrate Potassium; Metronidazole; Tetracycline: Foscarnet is administered by slow intravenous infusion. Foscarnet exhibits triphasic kinetics. Major Both QT prolongation and torsade de pointes TdP have been reported during postmarketing use of foscarnet.